SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting -November 01, 2023 at 06:31 am EDT
- Nirogacestat Therapy Demonstrated Fast and Sustained Enhancements in Practical Standing In comparison with Placebo Throughout ...
Read more
